Eprex

Eprex

epoetin alfa

Manufacturer:

Janssen-Cilag

Distributor:

DKSH
Concise Prescribing Info
Contents
Epoetin α
Indications/Uses
Treatment of symptomatic or transfusion-requiring anemia associated w/ chronic renal failure. Reduction of RBC transfusion requirements in AZT-treated HIV-infected patients w/ inappropriately low endogenous r-HuEPO levels.
Dosage/Direction for Use
Recommended starting dose: 50 U/kg, 3 times/wk, administered as IV inj over 1-2 min or SC inj. Max dose: Not >200 U/kg 3 times/wk.
Special Precautions
Hypersensitivity. Chronic renal failure anemia; AZT-treated HIV-infected patients; uncontrolled HTN; ischemic vascular disease. History of seizures. Do not administer by IV infusion or in conjunction w/ other drug soln. Monitor Hb, BP & serum electrolytes. Pregnancy & lactation. Childn.
Adverse Reactions
Increased BP; thrombosis of vascular access sites eg fistula; flu-like symptoms, bone pain & chills following inj; seizures; skin reactions, palpebral edema, possibly allergic in nature.
MIMS Class
Haematopoietic Agents
ATC Classification
B03XA02 - darbepoetin alfa ; Belongs to the class of other antianemic preparations. Used in the treatment of anemia.
Presentation/Packing
Form
Eprex pre-filled syringe 10,000 IU/mL
Packing/Price
1's
Form
Eprex prefilled syringe 2000 IU/0.5 mL
Packing/Price
1's
Form
Eprex prefilled syringe 4000 units/0.4 mL
Packing/Price
1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in